Drugs targeting the Ca2+-calcineurin/NFATC1-ACP5 axis in RANK-expressing CRC might be needed, such as the inhibitors CsA, 2APB, and U73122 used in the present study. This evidence concerns the gene ACP5 and colorectal carcinoma.